TrialScientific reports2022

Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial.

Tito R Mendoza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.